Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIndivior Regulatory News (INDV)

Share Price Information for Indivior (INDV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,240.00
Bid: 1,240.00
Ask: 1,245.00
Change: -37.00 (-2.90%)
Spread: 5.00 (0.403%)
Open: 1,277.00
High: 1,284.00
Low: 1,240.00
Prev. Close: 1,277.00
INDV Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

30 Dec 2022 12:28

RNS Number : 3785L
Indivior PLC
30 December 2022
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BN4HT335

Issuer Name

INDIVIOR PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

JPMorgan Chase & Co.

City of registered office (if applicable)

 

Country of registered office (if applicable)

US

4. Details of the shareholder

Name

City of registered office

Country of registered office

J.P. Morgan Securities plc

5. Date on which the threshold was crossed or reached

12-Oct-2022

6. Date on which Issuer notified

29-Dec-2022

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

3.418593

3.951037

7.369630

10142502

Position of previous notification (if applicable)

2.238554

3.958849

6.197403

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BN4HT335

4704860

3.418593

Sub Total 8.A

4704860

3.418593%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

Depository Receipt

n/a

n/a

5

0.000004

Sub Total 8.B1

5

0.000004%

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

Cash-settled Equity Swap

24/10/2022

24/10/2022

Cash

145400

0.105649

Cash-settled Equity Swap

28/10/2022

28/10/2022

Cash

307505

0.223436

Cash-settled Equity Swap

07/02/2023

07/02/2023

Cash

1194152

0.867681

Cash-settled Equity Swap

01/03/2023

01/03/2023

Cash

2266

0.001646

Cash-settled Equity Swap

08/03/2023

08/03/2023

Cash

555791

0.403843

Cash-settled Equity Swap

17/03/2023

17/03/2023

Cash

1282764

0.932068

Cash-settled Equity Swap

17/05/2023

17/05/2023

Cash

1266950

0.920577

Cash-settled Equity Swap

30/05/2023

30/05/2023

Cash

128182

0.093138

Cash-settled Equity Swap

02/06/2023

02/06/2023

Cash

6517

0.004735

Cash-settled Equity Swap

19/07/2023

19/07/2023

Cash

8990

0.006532

Cash-settled Equity Swap

22/09/2023

22/09/2023

Cash

4600

0.003342

Cash-settled Equity Swap

27/09/2023

27/09/2023

Cash

1559

0.001133

Cash-settled Equity Swap

12/10/2023

12/10/2023

Cash

10652

0.007740

Cash-settled Equity Swap

07/11/2023

07/11/2023

Cash

1140

0.000828

Cash-settled Equity Swap

14/11/2023

14/11/2023

Cash

11992

0.008713

Cash-settled Equity Swap

04/12/2023

04/12/2023

Cash

35706

0.025944

Cash-settled Equity Swap

05/05/2027

05/05/2027

Cash

327072

0.237653

Cash-settled Equity Swap

02/06/2027

02/06/2027

Cash

146399

0.106375

Sub Total 8.B2

5437637

3.951033%

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

JPMorgan Chase & Co.

J.P. Morgan Securities plc

3.369723

3.951036

7.320758%

JPMorgan Chase & Co.

JPMorgan Chase Bank, National Association

JPMorgan Chase & Co.

J.P. Morgan SE

JPMorgan Chase & Co.

J.P. Morgan Securities LLC

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

Chain of controlled undertakings:JPMorgan Chase & Co.JPMorgan Chase Bank, National Association (100%)J.P. Morgan International Finance Limited (100%)J.P. Morgan Capital Holdings Limited (100%)J.P. Morgan Securities plc (100%)JPMorgan Chase & Co.JPMorgan Chase Bank, National Association (100%)JPMorgan Chase & Co.JPMorgan Chase Bank, National Association (100%)J.P. Morgan International Finance Limited (100%)J.P. Morgan SE (100%)JPMorgan Chase & Co.JPMorgan Chase Holdings LLC (100%)J.P. Morgan Broker-Dealer Holdings Inc. (100%)J.P. Morgan Securities LLC (100%)

12. Date of Completion

29-Dec-2022

13. Place Of Completion

London

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFDIFESEESEEE
Date   Source Headline
1st Jul 20197:00 amRNSTotal Voting Rights
25th Jun 20197:00 amRNSHolding(s) in Company
18th Jun 201912:31 pmRNSIndivior Presents RECOVER Study Data at CPDD 2019
14th Jun 20198:47 amRNSHolding(s) in Company
29th May 20197:00 amRNSHolding(s) in Company
24th May 20199:04 amRNSHolding(s) in Company
17th May 20199:55 amRNSHolding(s) in Company
16th May 20197:00 amRNSIndivior to Participate in Conference
15th May 20197:00 amRNSDirector/PDMR Shareholding
13th May 20193:43 pmRNSDirector/PDMR Shareholding
13th May 20197:00 amRNSHolding(s) in Company
13th May 20197:00 amRNSHolding(s) in Company
9th May 201911:30 amRNSLicensing of PERSERIS in Canada
9th May 201910:29 amRNSBlock listing Interim Review
8th May 20191:54 pmRNSResult of AGM
3rd May 20197:00 amRNSHolding(s) in Company
2nd May 201912:00 pmRNS1st Quarter Results
2nd May 20197:00 amRNSHolding(s) in Company
1st May 20199:56 amRNSHolding(s) in Company
29th Apr 20194:16 pmRNSHolding(s) in Company
29th Apr 20191:35 pmRNSHolding(s) in Company
29th Apr 20191:25 pmRNSHolding(s) in Company
29th Apr 20191:16 pmRNSHolding(s) in Company
18th Apr 20199:24 amRNSChange of Registered Office
17th Apr 20193:26 pmRNSHolding(s) in Company
10th Apr 20197:00 amRNSStatement of Indivior on Grand Jury Indictment
9th Apr 20197:00 amRNSHolding(s) in Company
8th Apr 20199:18 amRNSIndivior publishes new research on opioid use disorder
8th Apr 20197:00 amRNSIndivior Presents RECOVER Study Data at ASAM 2019
5th Apr 20191:30 pmRNSIndivior Announces New Data at ASAM Conference
4th Apr 20197:00 amRNSNotice of Results
3rd Apr 201910:38 amRNSHolding(s) in Company
18th Mar 20194:27 pmRNSHolding(s) in Company
15th Mar 20195:00 pmRNSHolding(s) in Company
14th Mar 20192:00 pmRNSAnnual Financial Report
8th Mar 20192:30 pmRNSDirectorate Change
7th Mar 20192:00 pmRNSPatient-centered Outcomes Published
6th Mar 201910:37 amRNSDirector/PDMR Shareholding
4th Mar 20194:54 pmRNSHolding(s) in Company
1st Mar 20197:00 amRNSTotal Voting Rights
28th Feb 20193:31 pmRNSHolding(s) in Company
27th Feb 20191:00 pmRNSIndivior Launches PERSERIS (risperidone)
26th Feb 20193:10 pmRNSDirector Declaration
20th Feb 20199:06 amRNSHolding(s) in Company
20th Feb 20197:00 amRNSIndivior Launches SUBOXONE Film Authorized Generic
19th Feb 20197:00 amRNSThe Lancet Publishes Phase 3 Results of SUBLOCADET
14th Feb 20197:00 amRNSFinal Results
12th Feb 20197:00 amRNSFederal Court Denies Motion to Stay
5th Feb 20197:00 amRNSIndivior Responds to CAFC Rehearing Decision
4th Feb 20197:05 amRNSIndivior Enters into Agreement with Alvogen

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.